Redeye has a positive view on the fact that Synact has secured SEK 32.4 million through subscription of warrants (TO 2). The interest to participate was high, resulting in a subscription rate of almost 99%. In line with the company, we estimate that Synact in now funded to reach significant milestones, such as top-line readouts from the phase II trials in RA and NS. An important upcoming value inflection point for the company is interim data readout from the RA trial, which we expect to be presented late Q3.